Studying of the interleukin-36γ expression level in the skin of patients with plaque psoriasis

Cover Page


Cite item

Full Text

Abstract

Currently, it has been established that the cytokines of the IL-36 family occupy a significant place in the initiation and regulation of the inflammatory process in psoriasis.

Objective: studying the expression level of IL-36γ cytokines in the skin of patients with plaque psoriasis.

Material and methods. Skin biopsy specimens of 31 patients with plaque psoriasis were studied. The comparison group consisted of 20 biopsy samples of the skin of patients with lichen simplex, discoid eczema, lichen planus, mycosis fungoides (plaque stage). As a control group studied the skin bioptates of 10 healthy people. An immunohistochemical study of the skin was carried out using anti-IL-36γ antibodies.

Results. An increase in the relative expression area of IL-36γ in the affected skin of patients with plaque psoriasis (7.4 %) was found, compared with the unaffected areas (0.10 %) and the control group (0 %). The expression of IL-36γ in the skin of patients with psoriasis in the progressive period (8.85 %) was 1.42 times higher than in the stationary period of the disease (6.2 %). A strong direct relationship was revealed (r = 0.71) between the level of IL-36γ expression in the affected skin and the value of the PASI index, a moderate direct relationship between the level of IL-36γ expression and epidermal thickness (r = 0.34). In the affected skin of psoriasis patients, expressed expression of IL-36γ was observed in the upper layers of the epidermis, patients of the comparison group (discoid eczema, lichen simplex, lichen planus, mycosis fungoides) were weak or moderate, in the unaffected areas of the skin of patients with psoriasis and healthy people — weak or absent.

Findings. It was found that the expression of IL-36γ in the skin of patients with plaque psoriasis is significantly higher than with other skin diseases. The data obtained allow us to consider this cytokine as a possible diagnostic marker and use it in the differential diagnosis. 

About the authors

A. Yu. Pashkin

The 3d Military Hospital, National Guard Forces

Email: alek-pashkin@yandex.ru

Dermatovenerologist, Head of the Department,

Tsimbalina str., 36. Saint Petersburg, 192171

Россия

A. S. Zhukov

S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation

Email: doctor-vma@mail.ru

Cand. Sci. (Med.), Doctoral Student, Department of Skin and Sexually Transmitted Diseases,

Akademika Lebedeva str., 6, Saint Petersburg, 194044

Россия

V. R. Khairutdinov

S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation

Author for correspondence.
Email: haric03@list.ru

Dr. Sci. (Med.), Assoc. Prof., Department of Skin and Sexually Transmitted Diseases,

Akademika Lebedeva str., 6, Saint Petersburg, 194044

Россия

I. E. Belousova

S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation

Email: irena.belousova@mail.ru

Dr. Sci. (Med.), Assoc. Prof., Prof., Department of Skin and Sexually Transmitted Diseases,

Akademika Lebedeva str., 6, Saint Petersburg, 194044

Россия

A. V. Samtsov

S. M. Kirov Military Medical Academy, Ministry of Defence of the Russian Federation

Email: avsamtsov@mail.ru

Dr. Sci. (Med.), Prof., Head of the Department of Skin and Sexually Transmitted Diseases, 

Akademika Lebedeva str., 6, Saint Petersburg, 194044

Россия

A. V. Garabagiou

Saint Petersburg State Institute of Technology (Technical University)

Email: gar-54@mail.ru

Dr. Sci. (Chemistry), Prof., Vice-Rector for Scientific Work,

Moskovskiy prospect, 26, Saint Petersburg, 190013

Россия

References

  1. Хайрутдинов В. Р., Белоусова И. Э., Самцов А. В. Иммунный патогенез псориаза. Вестник дерматологии и венерологии. 2016;(4):20–26.
  2. Пашкин А. Ю., Воробьева Е. И., Хайрутдинов В. Р, Белоусова И. Э., Самцов А. В., Гарабаджиу А. В. Роль цитокинов семейства интерлейкина-36 в иммунопатогенезе псориаза. Медицинская иммунология. 2018;20(2):163–170.
  3. Vigne S., Palmer G., Martin P. et al. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1polarization of naive CD4+ T cells. Blood. 2012;120(17):3478–3487.
  4. Boutet M. A., Bart G. Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn’s disease. Clin Exp Immunol. 2016;184(2):159–173.
  5. Towne J. E., Garka K. E., Renshaw B. R., Virca G. D., Sims J. E. Interleukin (IL)-1F6, IL-1F8, and IL-1F9 signal through IL-1Rrp2 and IL1RAcP to activate the pathway leading to NF-kappaB and MAPKs. J Biol Chem. 2004;279(14):13677–13688.
  6. Günther S., Sundberg E. J. Molecular determinants of agonist and antagonist signaling through the IL-36 receptor. J Immunol. 2014;193(2):921–930.
  7. Gabay C., Towne J. E. Regulation and function ofinterleukin-36 cytokines in homeostasis and pathological conditions. J Leukoc Biol. 2015;97(4):645–652.
  8. Buhl A. L., Wenzel J. Interleukin-36 in infectious and inflammatory skin diseases. Front Immunol. 2019;10:1162.
  9. Dietrich D., Gabay C. IL 36 has proinflammatory effects in skin but not in joints. Nat Rev Rheumatol. 2014;10(11):639–640.
  10. Chau T., Parsi K. K., Ogawa T., Kiuru M., Konia T., Li C.-S. et al. Psoriasis or not? Review of 51 clinically confirmed cases reveals an expanded histopathologic spectrum of psoriasis. Journal of Cutaneous Pathology. 2017;44(12):1018–1026.
  11. D’Erme A. M., Wilsmann-Theis D., Wagenpfeil J. et al. IL36gamma (IL1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol. 2015;135(4):1025–1032.
  12. Fredriksson T., Pettersson U. Severe psoriasis — oral therapy with a new retinoid. Dermatologica. 1978;157(4):238–244.
  13. Towne J. E., Renshaw B. R., Douangpanya J., Lipsky B. P., Shen M., Gabel C. A. et al. Interleukin-36 (IL-36) ligands require processing for full agonist (IL-36 alpha, IL-36 beta, and IL- 36 gamma) or antagonist (IL-36Ra) activity. J Biol Chem. 2011;286(49):42594–42602.
  14. Foster A. M., Baliwag J., Chen C. S. et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J Immunol. 2014;192(12):6053–6061.
  15. Vigne S., Palmer G., Lamacchia C., Martin P., Talabot-Ayer D., Rodriguez E. et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood. 2011;118(22):5813–5823.
  16. Carrier Y, Ma H. L., Ramon H. E., Napierata L., Small C., O’Toole M. et al. Inter-regulation of Th17 cytokines and the IL-36 cytokines in vitro and in vivo: implications in psoriasis pathogenesis. J Invest Dermatol. 2011;131(12):2428–2437.
  17. Friedrich M., Tillack C., Wollenberg A., Schauber J., Brand S. IL36 gamma sustains a proinflammatory self-amplifying loop with IL17C in anti TNF induced psoriasiform skin lesions of patients with Crohn’s disease. Inflamm Bowel Dis. 2014;20(11):1891–1901.
  18. Johnston A., Fritz Y., Dawes S. M. et al. Keratinocyte overexpression of IL-17C promotes psoriasiform skin inflammation. J Immunol. 2013;190(5):2252–2262.
  19. Milora K. A., Fu H., Dubaz O., Jensen L. E. Unprocessed Interleukin-36α Regulates Psoriasis-Like Skin Inflammation in Cooperation with Interleukin-1. J Invest Dermatol. 2015;135(12):2992–3000.
  20. Muhr P., Zeitvogel J., Heitland I., Werfel T., Wittmann M. Expression of interleukin (IL)-1 family members upon stimulation with IL-17 differs in keratinocytes derived from patients with psoriasis and healthy donors. Br J Dermatol. 2011;165(1):189–193.
  21. Tecchio C., Micheletti A., Cassatella M. A. Neutrophil-derived cytokines: facts beyond expression. Front Immunol. 2014;5:508.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Pashkin A.Y., Zhukov A.S., Khairutdinov V.R., Belousova I.E., Samtsov A.V., Garabagiou A.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies